The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses

Eui-Cheol Shin; Ji Won Han; Wonseok Kang; Takanobu Kato; Seong-Jun Kim; Jin Zhong; Seungtaek Kim; Su-Hyung Park; Pil Soo Sung; Koichi Watashi; Jun Yong Park; Marc P Windisch; Jong-Won Oh; Takaji Wakita; Kwang-Hyub Han; Sung Key Jang

doi:10.3390/v12030302

The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses

Viruses. 2020 Mar 11;12(3):302. doi: 10.3390/v12030302.

Authors

Eui-Cheol Shin¹, Ji Won Han¹, Wonseok Kang², Takanobu Kato³, Seong-Jun Kim⁴, Jin Zhong^{5

6}, Seungtaek Kim⁷, Su-Hyung Park¹, Pil Soo Sung⁸, Koichi Watashi³, Jun Yong Park⁹, Marc P Windisch¹⁰, Jong-Won Oh¹¹, Takaji Wakita³, Kwang-Hyub Han⁹, Sung Key Jang¹²

Affiliations

¹ Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea.
² Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
³ Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
⁴ Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea.
⁵ Unit of Viral Hepatitis, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.
⁶ University of Chinese Academy of Sciences, Beijing 100049, China.
⁷ Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam 13488, Korea.
⁸ Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul 06591, Korea.
⁹ Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Korea.
¹⁰ Applied Molecular Virology Laboratory, Institut Pasteur Korea, Seongnam 13488, Korea.
¹¹ Department of Biotechnology, Yonsei University, Seoul 03722, Korea.
¹² Department of Life Sciences, Pohang University of Science and Technology, Pohang 37673, Korea.

Abstract

: Hepatitis C virus (HCV) infects ~71 million people worldwide, and 399,000 people die annually due to HCV-related liver cirrhosis and hepatocellular carcinoma. The use of direct-acting antivirals results in a sustained virologic response in >95% of patients with chronic HCV infection. However, several issues remain to be solved to eradicate HCV. At the 26th International Symposium on Hepatitis C Virus and Related Viruses (HCV2019) held in Seoul, South Korea, October 5-8, 2019, virologists, immunologists, and clinical scientists discussed these remaining issues and how we can achieve the elimination of HCV.

Keywords: antivirals; flavivirus; hepatitis C virus; liver diseases; vaccine.

Publication types

Congress
Research Support, Non-U.S. Gov't

MeSH terms

Adaptive Immunity
Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use
Disease Management
Disease Susceptibility
Hepacivirus / physiology*
Hepatitis C / complications
Hepatitis C / drug therapy
Hepatitis C / prevention & control
Hepatitis C / virology*
Host-Pathogen Interactions / immunology
Humans
Immunity, Innate
Liver Cirrhosis / etiology
Liver Neoplasms / etiology
Viral Vaccines / administration & dosage
Viral Vaccines / immunology
Virus Assembly
Virus Internalization
Virus Replication

Substances

Antiviral Agents
Viral Vaccines